European Commission on Public Health defines rare diseases as
- life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them -
Rare Insight Consulting
- will help new start-up biopharmaceutical companies establish their presence in Italy & Europe, as well as assisting well-established companies to bring solutions to people suffering from severe or orphan diseases. -
Rare Insight has been and is an extremely valuable partner for Laboratoires CTRS.
They have effectively supported us in all phases (early access, price & reimbursement, launch strategy and tactics in the Italian market, KOL mapping, effective presentation of Orphacol advantages to treating physicians) allowing Orphacol to reach 100% of eligible patients.
Marco Liguori – Head of International Commercial Operations
There were some markets that were more difficult, in terms of previous relations we had with the Key Opinion Leaders, I have in mind for instance UK and ITALY and for some of these countries we have been able really to repair the relationships because of the local presence that was built.
Xavier Paoli – Pharnext Chief Commercial Officer
We are proud to see that our local presence, combined with strong experience and flexibility has been appreciated and made possible the development of the project in Italy, in coordination with our strategic partner BlueDil International.
Watch our partner testimony In the video below.